PMID: 8580733Nov 1, 1995Paper

Cyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse

Neuromuscular Disorders : NMD
J T VilquinJacques P Tremblay

Abstract

Cyclophosphamide immunosuppression does not permit successful myoblast allotransplantation in mouse. Myoblast transplantation is a potential treatment for Duchenne muscular dystrophy. In one clinical trial, Duchenne patients were immunosuppressed with cyclophosphamide. We report here that myoblasts from transgenic mice expressing the beta-galactosidase reporter gene transplanted in mdx mice failed to form new muscle fibres when cyclophosphamide (2 or 10 mg kg-1 per day) was used for immunosuppression. At the lowest dose of cyclophosphamide (2 mg kg-1 per day), some mdx recipient mice formed antibodies against donor myoblasts; however, no humoral immune reaction was observed at the highest dose (10 mg kg-1 per day). The failure of transplantation under cyclophosphamide treatment was attributed to the low immunosuppressive activity at a low dose and to the toxic action of a high dose of this drug. These results could explain the lack of success of myoblast transplantation in a previous clinical trial.

References

May 1, 1992·Muscle & Nerve·J HuardJ P Tremblay
Oct 1, 1989·Seminars in Oncology·D C DollJ W Yarbro
Apr 1, 1993·Journal of the Neurological Sciences·J E MorganT A Partridge
Feb 15, 1995·Transplantation·J T VilquinJ P Tremblay
Sep 1, 1993·Neuromuscular Disorders : NMD·J P TremblayM Tremblay
Apr 1, 1993·Toxicon : Official Journal of the International Society on Toxinology·B FrancisI I Kaiser
Jul 1, 1993·Annals of Neurology·G KarpatiM Vanasse
Jan 1, 1962·Annual Review of Medicine·P CALABRESI, A D WELCH

❮ Previous
Next ❯

Citations

Sep 28, 2010·Surgery Today·Beniamino Palmieri, Jacques P Tremblay
Jun 1, 2005·Experimental Cell Research·Y C KocaefeL Garcia
Feb 3, 1998·Neuromuscular Disorders : NMD·V BrusseeJ P Tremblay
Mar 28, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Bruno PéaultJohnny Huard
May 18, 2013·Tissue Engineering. Part B, Reviews·Jonathan Mark FishmanPaolo De Coppi
Oct 22, 2003·Current Opinion in Rheumatology·Daniel Skuk, Jacques P Tremblay
Feb 1, 1997·Brain Research. Molecular Brain Research·O GriesbeckH Thoenen
Jun 3, 1998·Neuromuscular Disorders : NMD·H ItoJ P Tremblay
Dec 2, 2004·Expert Opinion on Biological Therapy·Daniel Skuk
Oct 11, 2005·Physical Medicine and Rehabilitation Clinics of North America·Baohong CaoJohnny Huard
Mar 25, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Daniel SkukJacques P Tremblay
Aug 10, 2000·Molecular Therapy : the Journal of the American Society of Gene Therapy·G M SmytheM D Grounds
May 13, 2006·Journal of Neuropathology and Experimental Neurology·Daniel SkukJacques P Tremblay
Feb 19, 2000·Microscopy Research and Technique·D Skuk, J P Tremblay
Sep 19, 2020·The Journal of Clinical Investigation·Stefano BiressiThomas A Rando

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.